CXC chemokine receptor 4 (CXCR4) is an essential regulator for homing, and maintenance of hematopoietic stem cells within the bone marrow niches. In the analyses of clinical implications of bone marrow CXCR4 expression in patients with acute myeloid leukemia, we not only found higher CXCR4 expression was an independent poor prognostic factor, irrespective of age, white blood cell counts, cytogenetics, and mutation status of NPM1/ FLT3-ITD and CEBPA, but also showed CXCR4 expression was inversely associated with mutations of CEBPA, a gene encoding transcription factor C/EBPα. Patients with wild-type CEBPA had significantly higher CXCR4 expression than those with mutated CEBPA. We hypothesized that CEBPA might influence the expression of CXCR4. To test the hypothesis, we first examined endogenous CXCR4 expression in 293T and K562 cells overexpressing wild-type C/EBPα p42 and demonstrated that CXCR4 levels were increased in these cells, whilst the expression of the N-terminal mutant, C/EBPα p30, diminished CXCR4 transcription. We further showed p42 was bound to the CXCR4 promoter by the chromatin immunoprecipitation assays. Induction of p42 in the inducible K562-C/EBPα cell lines increased the chemotactic migration. Moreover, decreased expression of C/EBPα by RNA interference decreased levels of CXCR4 protein expression in U937 cells, thereby abrogating CXCR4-mediated chemotaxis.
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The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 cancers were proved to metastasize to the bones and lymph nodes in a SDF-1-dependent manner in which the bone marrow (BM) in particular provided a protective environment for tumor cells. 3, 4 Furthermore, in mouse models, acute myeloid leukemia (AML) cells were shown to express functional CXCR4 that induced chemotaxis and migration of leukemia cells beneath BM stromal cells. 5, 6 Expression of CXCR4 in leukemic cells was associated with cell cycle arrest and reduced numbers of cell divisions, providing a potential mechanism for leukemia cells to evade the cell-killing effect of chemotherapy. 2 Higher expression of CXCR4, measured by either immunohistochemical method or flow cytometry, has been identified as a poor prognostic marker for AML 7, 8 and may be an attractive target for the development of novel therapeutic approaches. 9 However, whether the prognostic implication of higher CXCR4 expression on survival is independent from other prognostic factors, such as recently found genetic markers FLT3-ITD, NPM1 and CEBPA mutations, remains unclear.
AML is a heterogeneous hematologic malignancy characterized by proliferation but impaired differentiation of myeloid progenitors. The leukemogenesis is a multi-step process involving accumulated genetic abnormalities and epigenetic deregulations that perturb gene expression and disrupt cell differentiation.
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Transcription factors are main targets of mutations in AML. CCAAT enhancer binding protein alpha (C/EBPα) is a 42-kDa transcription factor that contains two transactivation domains (TAD, TAD1 and TAD2) in the amino terminus and a basic leucine zipper domain (bZIP) at its carboxy terminus for DNA binding. 11, 12 Mutations in one or both alleles of CEBPA are reported in about 7% to 15% of patients with AML. 13, 14 These mutations can be divided into two major categories: one comprises C-terminal mutations that disrupt the bZIP region and the other comprises N-terminal mutations that disrupt the reading frame, resulting in translation of a 30-kDa C/EBPα p30 isoform. The N-terminal truncated mutant was shown to have a dominant-negative effect. 11, 12 Though AML patients with C/EBPα mutant have favorable prognosis, 13, 15 the molecular mechanisms how CEBPA mutations contribute to better treatment response and improved outcomes are not yet fully understood.
In the present study, we analyzed the BM CXCR4 expression by quantitative real-time polymerase chain reaction (RT-QPCR) in a cohort of 220 adult patients with de novo AML and found higher CXCR4 expression was an independent poor prognostic factor. Moreover, CXCR4 expression was inversely associated with CEBPA mutation. In the study of the mechanism of this relationship between CXCR4 expression and CEBPA mutation, we found that C/EBPα activates CXCR4 transcription through direct binding to its promoter. We further demonstrated that the overexpression of C/EBPα increased SDF1-mediated directional migration of leukemic cells, while the depletion of C/EBPα diminished cell migration. These results indicate a role of C/EBPα in transcriptional control of CXCR4 gene expression and emphasize the importance of this transcription factor in the regulation of chemotactic SDF-1/CXCR4 axis in AML cells.
Methods

Patients and samples
Totally, 220 adult patients who were newly diagnosed as having de novo AML at the National Taiwan University Hospital (NTUH), had enough cryopreserved cells for molecular analyses, and had complete clinical and laboratory data were recruited for this study. Gene Expression Assay (Assay ID,Hs02330069_s1, Applied Biosystems). Each sample was tested at least twice independently. The amount of the target gene was normalized to that of the housekeeping gene RPLP0. The copies of target gene were quantified only after successful amplification of the internal control, using the standard curves derived from cloned plasmids. All data were presented as log ratio of the target gene/RPLP0. were performed as previously described. Abnormal sequencing results were confirmed by at least 2 repeated analyses.
Mutation analysis
Statistical analysis
The discrete variables of patients with lower and higher BM CXCR4 expression were compared using the Chi-square tests or Fisher's exact test. We used Mann-Whitney U-test to compare continuous variables and medians of distributions.
Whole patient population was included for analyses of the correlation between CXCR4 expression and clinical characteristics, however, only those receiving conventional standard chemotherapy, as mentioned above, were included in analyses of survivals.
Overall survival (OS) was measured from the date of first diagnosis to death from any cause or the last follow-up, whereas relapse was defined as a reappearance of at least 5% leukemic blasts in a BM aspirate or new extramedullary leukemia in patients with a previously documented remission. We adopted Kaplan-Meier estimation to plot survival curves, and used log-rank tests to examine the difference between groups.
Relative risk (RR) and 95% confidence interval (CI) were estimated by Cox proportional hazards regression models to determine independent risk factors associated with survival in multivariate analyses. Two-sided P-values less than 0.05 were considered statistically significant. All statistical analyses were accomplished with the SPSS 17 (SPSS Inc., Chicago, IL, USA) and Statsdirect (Cheshire, England,
UK)
Results
Correlation of BM CXCR expression with clinical and biological features and treatment outcome
The median value of BM CXCR4 expression in AML patients was used as the cut-off point to define lower-and higher-expression groups. Patients with higher BM CXCR4 expression were male predominant, older and had lower serum lactate dehydrogenase levels than those with lower expression ( Figure 2D . These data clearly show C/EBPα p42 as an activator of the CXCR4 promoter.
C/EBPα activates the CXCR4 transcription through direct binding to its promoter
To examine the functional contribution of these putative C/EBPα binding sites to the CXCR4 promoter activity, we introduced mutation at those sites in the pGL2-CXCR4-0.8Kb reporter construct and measured the promoter activity mediated by C/EBPα p42 using luciferase activity assay. As shown in Figure 3A , the mutation at S1 or S2 site did not abolish the C/EBPα p42-mediated CXCR4 promoter activity.
In contrast, the promoter activity decreased significantly when the S3 (-231/-246) site of the CXCR4 promoter was mutated, indicating the exclusive role of S3 site for C/EBPα p42-mediated transcriptional activation of CXCR4.
We then determined whether C/EBPα p42 could bind at the S3 site by gel-shift assays using the biotin-labeled double-stranded oligonucleotide covering S3 sequence of the CXCR4 promoter. Incubation of this probe with nuclear extract of HEK293T cells ectopically expressing C/EBPα p42 gave rise to the formation of a DNA-protein complex. This complex was shifted to higher molecular weight sites by the addition of the Flag peptides specific M2 or C/EBPα antibody, indicating the presence of C/EBPα and thus the bound antibody in the complex, but not by the GAPDH antibody ( Figure 3B , lane 3-5, 11-12). The C-terminal mutant (CTM) also formed a complex with the probe ( Figure 3B , lane 6). In contrast, p30 did not bind to the S3 probe ( Figure 3B , lane 7). In addition, co-incubation of nuclear lysate containing p30 diminished the binding of p42 or CTM to the S3 probe ( Figure 3B , lanes 9 and 10).
Next, we performed ChIP to test whether C/EBPα is directly involved in regulating the CXCR4 promoter in HEK293T cells expressing Flag-p42 or Flag-p30. Primers specific to the CXCR4 promoter were used for the PCR reaction. The result showed that wild-type C/EBPα p42 was associated with the CXCR4 promoter, whereas the mutant p30 was not ( Figure 3D ). Similar results were observed when ChIP assays were performed using primers specific for the Albumin promoter in the PCR, consistent with the previous report that C/EBPα binds to the Albumin promoter. 32 PCR using β-actin promoter primers was performed as the negative control. Based on these data, we conclude that C/EBPα is a direct activator of the CXCR4 promoter.
Ectopic expression of C/EBPα p42 increased the chemotactic migration in K562 cells in response to SDF-1 treatment
To test whether ectopic expression of C/EBPα p42 or p30 in AML cells affects leukemic cell migration, the chemotaxis assays were performed. The inducible K562-C/EBPα cells stably expressed wild type or mutated C/EBPα were established.
The pTripz-C/EBPα−p42 or p30 plasmids were packaged using HEK293T cells and transduced into K562 cells as described. 33 We used K562 cells because they do not express endogenous C/EBPα. 34 Expression of C/EBPα p42 and C/EBPα p30 after the cells were exposed to doxycycline was successfully confirmed by Western blot analysis ( Figure 4A ).
To test whether the p42-mediated transcriptional activation of the CXCR4 gene can also be detected in the K562-C/EBPα p42 stable cell line, Western blot and RT-qPCR analysis were performed in these cells with or without doxycycline treatment. As shown in Figure 4A -B, CXCR4 protein and mRNA level were increased in K562-C/EBPα p42 cells after doxycycline treatment for 24 h. In contrast, expression of CXCR4 was not activated when p30 was induced. Protein and CXCR4 mRNA levels were not affected by doxycycline treatment in K562 parental cells.
CXCR4 surface protein expression was also assessed using flow cytometry. As expected, surface CXCR4 expression was significantly increased in K562-C/EBPα p42 cells, but not K562-C/EBPα p30 cells, after doxycycline treatment.
U937 cells were used as the positive control for the assay ( Figure 4C ).
To further assess the in vitro functional responses of K562-C/EBPα stable cell lines, the migration of the cells in response to the SDF-1 treatment after C/EBPα was induced was examined. Consistent with increase of CXCR4 expression, induction of p42 in K562 cells significantly increased the migration index of these cells towards SDF-1. This chemotactic migration could be abolished by the treatment of AMD3100, a specific inhibitor for CXCR4. In contrast, induction of p30 did not affect the chemotactic migration toward SDF1 in K562 cells ( Figure 4D ).
Depletion of CEBPA reduced chemotactic migration toward SDF-1 in U937 cells
Finally, we tested whether depletion of CEBPA in U937 cells reduce chemotactic migration toward SDF-1. We used U937 cells because they express high levels of endogenous C/EBPα. 34 Inducible U937 cell lines stably transfected with shCEBPA (U937-shCEBPA) or scramble control plasmid were established. Cells treated with doxycycline were subjected to Western blot analysis and in vitro migration assay. As shown in Figure 4E , C/EBPα protein level reduced with a concurrent decrease of CXCR4 expression in U937-shCEBPA cells after doxycycline treatment. Furthermore, the depletion of C/EBPα significantly decreased the migration index in response to SDF-1 ( Figure 4F ). These data suggest that wild-type C/EBPα induces CXCR4 expression and in turn increases the SDF-1-mediated directional migration of leukemic cells.
Discussion
In this study, we found CXCR4 expression was negatively associated with CEBPA mutation. Moreover, to the best of our knowledge, this study was the first to demonstrate a role of C/EBPα in transcriptional control of CXCR4 gene expression and emphasize the importance of this transcription factor in the regulation of chemotactic SDF-1/CXCR4 axis in AML cells.
In addition to genetic and epigenetic aberrations of hematopoietic progenitors, impaired BM microenvironment may also contribute to the development of AML. In the current study, we provided several evidences to demonstrate that wild-type C/EBPα truly regulates the expression of CXCR4, while mutant p30 loses this action.
Firstly, enforced expression of wild type C/EBPα-p42 increased CXCR4 protein and mRNA levels in 293T and K562 cells (Figures 1B and 1C and 4A and 4B) and it also activated the promoter activity of CXCR4 gene in 293T cells, while mutant p30 did not ( Figure 2 ). Secondly, ChIP assay indicated the binding of C/EBPα-p42, but not p30, in the CXCR4 promoter region ( Figure 3D ). Thirdly, we located the functional C/EBPα binding site at -231/-246 within the promoter region of CXCR4 gene ( Figure 3B ) and observed that mutation at the S3 (-231/-246) site caused a reduction of C/EBPα-p42-mediated activation of CXCR4 promoter ( Figure 3A ). Taken together, our results demonstrated that C/EBPα-p42 is a direct activator of CXCR4 transcription through direct binding to the CXCR4 promoter region, whereas the C/EBPα-p30 isoform cannot bind to the same region in vitro and in vivo. Furthermore, p30
diminished the binding of p42 or CTM to the S3 probe in the gel-shift assays ( Figure   3B , lanes 9 and 10) suggests that p30 acts as a dominant-negative isoform in the regulation of CXCR4 transcription. Similarly, Cleaves et al found the relative affinity of C/EBPα-p30 for C/EBP-binding sites on the GR and PU.1 genes were reduced compared with C/EBPα-p42. 37 In the NOD/SCID-leukemia mouse model, CXCR4
was reported to participate in the migration, repopulation, and development of AML cells in the BM by regulating their anchorage to the stromal microenvironment and cell survival. 6 How does the effect of CEBPA mutant on CXCR4 expression contribute to the leukemogenesis awaits further study.
We and others reported that AML patients with CEBPA mutation had favorable survival. 13, 14, 38 The better prognosis in AML with CEBPA mutation may be partially explained by the lower CXCR4 expression in these patients. CXCR4-mediated contact between leukemia cells and stromal cells has been shown to result in cell cycle arrest and reduced numbers of cell divisions, providing a potential mechanism for leukemia cells to escape chemotherapy effect. *The median value of CXCR4 expression in total population was used as the cut-off point to define lower-and higher-expression groups. †Number (%) of patients ‡Median (range)
∆
Only the 151 patients who received conventional intensive induction chemotherapy and then consolidation chemotherapy if CR was achieved, were included in the analysis. Two hundred and ten patients, including 104 higher CXCR4 and 106 lower CXCR4 patients, had chromosome data at diagnosis. There was no difference of cytogenetic changes such as simple, complex, t(8;21), t(15;17), inv(16), t(11q23), t(7;11), -5/5q-and -7/7q-between patients with higher and lower CXCR4 expression Abbreviation: CR, complete remission; PR, partial remission. 
Transfection and luciferase assays
HEK293T cells were transfected using a DNA mixture containing ScreenFect in vitro DNA transfection reagent (InCella). After transfection for 24 h, cells were analyzed for reporter activity assays. Transfected cells were assayed for both firefly and Renilla luciferase activities using the dual luciferase assay system (Promega).
Plasmid construction
The DNA fragment of CEBPA was obtained by PCR from K562 genomic DNA and cloned in-frame in the EcoRI and XhoI sites of pCMV-Tag2B plasmid. For generating tetracycline inducible plasmids, wild type CEBPA or p30 mutant cDNA were subcloned in the AgeI and XhoI sites of pTRIPZ plasmid. The human CEBPA shRNA were cloned into the lentiviral vector pTRIPZ plasmid containing a RFP reporter. The shRNA oligonucleotide sequence targeting CEBPA was as described.
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The pGL2-CXCR4 plasmid containing human CXCR4 promoter region fused to the promoterless pGL2 firefly luciferase reporter was a generous gift of Wilhelm Krek.
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The pGL2-CXCR4-0.8 kb was used to PCR amplify to generate a 0.2-kb fragment of the CXCR4 promoter region, which was subcloned to the pGL2 vector, producing pGL2-CXCR4-0.2 kb. Mutant versions of pCMV-tag2B-C/EBPpCMV-tag2B-C/EBP-CTM) and pGL2-CXCR4-0.8 kb (pGL2-CXCR4-S1, pGL2-CXCR4-S2 and pGL2-CXCR4-S3) were generated using Quick-Change Site-directed Mutagenesis kit.
Chromatin immunoprecipitation assays (ChIP)
Chromatin immunoprecipitation was performed as described 2 . In brief, cells were treated with formaldehyde at a final concentration of 1% for 10 min at room temperature. Glycine was added at a final concentration of 125 M to quench crosslinking. Cell lysates were sonicated to generate DNA fragments averaging <1 kb.
After pre-clearance, cell extracts were incubated with 1 g of antibody at 
Preparation of nuclear extracts and gel-shift analysis
The preparation of nuclear extracts from HEK293T cells expressing C/EBP and gel-shift reactions were as described previously 2 . The gel-shift analysis was performed using gel-shift assay kits from Signosis (Sunnyvale, CA). For super-shift assays, antibodies specific for C/EBPor GAPDH were added to the nuclear extracts for 30 min on ice prior to the DNA binding reaction. After incubation at room temperature for 30 min with biotin-labeled probes and nuclear extracts (5.0 g protein), samples were analyzed by electrophoresis at 150 V for 1.5 h through nondenaturing 4% polyacrylamide gels. After separation by 4% non-denaturing polyacrylamide gel electrophoresis, the binding reaction mixtures were transferred onto a nylon membrane, and the membrane was UV-cross-linked. The biotin-labeled DNA was probed with streptavidin-HRP conjugate for chemiluminescence detection.
Chemotaxis assay
A total of 5x10 5 cells in a volume of 200 l were added to the top chamber of
Transwell culture inserts (Corning Costar, Lowell, MA) with a pore size of 5 m.
Inserts were placed in wells containing 800 l of RPMI medium with or without SDF-1 (R&D Systems). Chemotaxis assays were performed at 37℃ for 24 hours.
Cells were then counted in triplicates using a hemocytometer. There is negative association of BM CXCR4 mRNA expression and CEBPA mutation (P=0.0019). Intriguingly, there is significant differences in CXCR4 mRNA expression between patients with CEBPA double mutations (CEBPA double-mut ) and those with single mutation (CEBPA single-mut , P=0.0075) or those without mutation (CEBPA wild , P=0.0002). expression had shorter overall survival than those with lower expression (P=0.03).
